Unknown

Dataset Information

0

Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome.


ABSTRACT: BACKGROUND:Despite advances in supportive care, moderate-severe acute respiratory distress syndrome (ARDS) is associated with high mortality rates, and novel therapies to treat this condition are needed. Compelling pre-clinical data from mouse, rat, sheep and ex vivo perfused human lung models support the use of human mesenchymal stem (stromal) cells (MSCs) as a novel intravenous therapy for the early treatment of ARDS. METHODS:This article describes the study design and challenges encountered during the implementation and phase 1 component of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of bone marrow-derived human MSCs for moderate-severe ARDS. A trial enrolling 69 subjects is planned (9 subjects in phase 1, 60 subjects in phase 2 treated with MSCs or placebo in a 2:1 ratio). RESULTS:This report describes study design features that are unique to a phase 1 trial in critically ill subjects and the specific challenges of implementation of a cell-based therapy trial in the ICU. CONCLUSIONS:Experience gained during the design and implementation of the START study will be useful to investigators planning future phase 1 clinical trials based in the ICU, as well as trials of cell-based therapy for other acute illnesses. TRIAL REGISTRATION: CLINICAL TRIALS REGISTRATION:NCT01775774 and NCT02097641.

SUBMITTER: Liu KD 

PROVIDER: S-EPMC4273700 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome.

Liu Kathleen D KD   Wilson Jennifer G JG   Zhuo Hanjing H   Caballero Lizette L   McMillan Melanie L ML   Fang Xiaohui X   Cosgrove Katherine K   Calfee Carolyn S CS   Lee Jae-Woo JW   Lee Jae-Woo JW   Kangelaris Kirsten N KN   Gotts Jeffrey E JE   Rogers Angela J AJ   Levitt Joseph E JE   Wiener-Kronish Jeanine P JP   Delucchi Kevin L KL   Leavitt Andrew D AD   McKenna David H DH   Thompson B Taylor BT   Matthay Michael A MA  

Annals of intensive care 20140703


<h4>Background</h4>Despite advances in supportive care, moderate-severe acute respiratory distress syndrome (ARDS) is associated with high mortality rates, and novel therapies to treat this condition are needed. Compelling pre-clinical data from mouse, rat, sheep and ex vivo perfused human lung models support the use of human mesenchymal stem (stromal) cells (MSCs) as a novel intravenous therapy for the early treatment of ARDS.<h4>Methods</h4>This article describes the study design and challenge  ...[more]

Similar Datasets

| S-EPMC7597675 | biostudies-literature
| S-EPMC4297579 | biostudies-literature
| S-EPMC8860258 | biostudies-literature
2021-05-20 | GSE160929 | GEO
2020-05-01 | GSE130362 | GEO
2023-06-20 | GSE231660 | GEO
2014-04-24 | E-GEOD-57011 | biostudies-arrayexpress
2014-05-07 | E-GEOD-57223 | biostudies-arrayexpress
| S-EPMC9330663 | biostudies-literature
| S-EPMC7565018 | biostudies-literature